父亲使用氨酸和儿童神经发育障碍的风险
Lin-Chieh Meng1,2,3,4, Marleen M H J van Gelder4, Hui-Min Chuang1,2
1Health Data Research Center, National Taiwan University, Taipei, Taiwan.
NEJM evidence
|February 24, 2026
概括
父亲在受孕前使用氨酸并没有增加后代神经发育障碍的风险. 这项大型队列研究在考虑混因素后没有发现任何关联.
科学领域:
- 生殖毒理学 生殖毒理学
- 神经发育障碍 神经发育障碍
- 药物遗传学 药物遗传学
背景情况:
- 人们对父亲在受孕前使用氨酸和后代神经发育障碍 (NDD) 存在担忧.
- 瓦尔酸是一种抗发作药物,具有潜在的原性作用.
研究的目的:
- 调查怀孕后90天内父亲暴露于瓦尔酸盐与后代NDD发生率之间的关联.
- 为了比较风险,使用人口控制,仅限于指示的分析和活跃的比较器.
主要方法:
- 在挪威和台湾进行了全国性队列研究,随访时间超过6年.
- 聚合后勤回归和倾向得分细分分层加权 (PS-FSW) 对调整后的分析.
- 暴露于烯酸盐的父亲的后代与未暴露的后代相比较,或与lamotrigine/levetiracetam对比.
主要成果:
- 原始分析显示NDD风险增加 (HR为1.67挪威,1.35台湾).
- 经过调整后,对受限指示群体的分析显示没有显著的关联 (aHR 1.20 挪威, 1.12 台湾).
- 积极对比分析也显示没有显著差异 (aHR 1.02 挪威, 1.22 台湾).
结论:
- 父亲在受孕前90天内使用氨酸与后代NDD风险增加无关.
- 对混因素的调整对于评估这种关联至关重要.
- 研究结果表明,酸的父性周周受孕暴露可能不会对NDD带来重大风险.
相关概念视频
Teratogenicity
4.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.3K
Factors Affecting Drug Response: Overview
3.2K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism
289
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
289
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
771
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
771
Drug Toxicity: Risk factors
55
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
55


